Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA9 | Q16790 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16019091 | 0.81 | — | — | |
| SCHEMBL23823928 | 0.79 | — | — | |
| SCHEMBL20432161 | 0.77 | DNM1 (0.33) | DNM1CA12CA1CA9ALDH1A1 | |
| SCHEMBL25676616 | 0.77 | EPHX2 (0.36) | DNM1CA12CA1CA9ALDH1A1 | |
| SCHEMBL22384450 | 0.76 | — | — | |
| SCHEMBL18887686 | 0.75 | DNM1 (0.32) | DNM1CA12CA1CA9ALDH1A1 | |
| SCHEMBL12512560 | 0.75 | DNM1 (0.32) | DNM1CA12CA1CA9ALDH1A1 | |
| SCHEMBL10664150 | 0.74 | CA12 (0.48) | DNM1CA12CA1CA9ALDH1A1 | |
| SCHEMBL498120 | 0.74 | — | — | |
| SCHEMBL28419117 | 0.74 | DNM1 (0.46) | DNM1CA12CA1CA9EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303201-B2 | Method of inhibiting the formation of gas hydrates using amidines and guanidines | ECO INHIBITORS AS (NO) | 2016-04-05 | — | — | US | disclosed |
| US-20140256599-A1 | METHOD OF INHIBITING THE FORMATION OF GAS HYDRATES USING AMIDINES AND GUANIDINES | ECO INHIBITORS AS (NO) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256599-A1 | METHOD OF INHIBITING THE FORMATION OF GAS HYDRATES USING AMIDINES AND GUANIDINES | MAGI3, GEMIN5, GCG | DNM1 310/4885CA12 1960/4885CA1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.